Pharmacoeconomics

CLINICAL PHARMACY AND PHARMACOLOGY 12m 50s 0.25 Credit CME Update on Dexamethasone for the Treatment of COVID-19 JAMA

DRUG DEVELOPMENT 1 Credit CME Missed Opportunities on Emergency Remdesivir Use JAMA

CLINICAL PHARMACY AND PHARMACOLOGY 36m 28s 0.5 Credit CME Remdesivir and Dexamethasone for the Treatment of COVID-19 JAMA

CLINICAL PHARMACY AND PHARMACOLOGY 1 Credit CME Ensuring Access to Medications in the US During the COVID-19 Pandemic JAMA

DRUG DEVELOPMENT 1 Credit CME The Equitable Distribution of COVID-19 Therapeutics and Vaccines JAMA

LUNG CANCER 1 Credit CME Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19 JAMA Oncology

PHARMACOECONOMICS National Drug Shortages: Reacting to Current Shortages and Proactively Anticipating the Future AMA

DRUG DEVELOPMENT 1 Credit CME Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies JAMA

DRUG DEVELOPMENT 1 Credit CME Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 JAMA

CLINICAL PHARMACY AND PHARMACOLOGY 1 Credit CME FDA Approval and Regulation of Pharmaceuticals, 1983-2018 JAMA

HEALTH CARE POLICY 25m 57s Waste in the US Health Care System: Estimated Costs and Potential for Savings JAMA

OPHTHALMOLOGY 9m 34s Waste in the US Health Care System JAMA

ETHICS 1 Credit CME Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? AMA Journal of Ethics

HEALTH CARE ECONOMICS, INSURANCE, PAYMENT 29m 44s Lowering Cost and Increasing Access to Drugs Without Hurting Innovation JAMA

PHARMACOECONOMICS 1 Credit CME Comparison of Ophthalmic Medication Prices Between the United States and Australia JAMA Ophthalmology

HEALTH CARE ECONOMICS, INSURANCE, PAYMENT 28m 56s Next Phase in Effective Cost Control in Health Care JAMA

SUBSTANCE USE AND ADDICTION 13m 19s Marketing of Opioid Products and Mortality From Opioid-Related Overdoses; Comparison of Wait Times for New Patients Between the Private Sector and VA Medical Centers JAMA Network Open

HEALTH CARE ECONOMICS, INSURANCE, PAYMENT 17m 31s Analysis of Proposed Medicare Reforms on Prescription Drug Total Spending and Patient Cost-Sharing JAMA Internal Medicine

DERMATOLOGY 16m 59s Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab vs Ipilimumab Alone for Unresectable Melanoma JAMA Dermatology

CLINICAL PHARMACY AND PHARMACOLOGY 1 Credit CME Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents JAMA